Loading organizations...
§ Private Profile · Suzhou, Jiangsu Province, China
Biopharmaceutical company develops bioconjugate drugs & ADCs using proprietary enzymatic conjugation tech for oncology.
GeneQuantum Healthcare is a Suzhou, China-based biopharmaceutical company that develops next-generation bioconjugate drugs, specifically antibody-drug conjugates for global oncology applications. The organization utilizes proprietary enzymatic site-specific conjugation technologies to support end-to-end drug development processes, advancing assets from initial design through commercial production. To expand its clinical pipeline, the firm partners with biotechnology companies such as Aimed Bio to co-develop up to five new targeted therapeutics for cancer and brain diseases. The enterprise has raised capital across multiple financing rounds, including a 40 million RMB Series A, a nearly 100 million RMB Pre-B, and a Series C round totaling hundreds of millions of RMB. These funding rounds were backed by institutional investors including China Life Private Equity, PICC Capital, and Sunshine Guojian. GeneQuantum Healthcare was founded in 2013 by Dr. Gang Qin.
GeneQuantum Healthcare has raised $20.8M across 2 funding rounds.
GeneQuantum Healthcare has raised $20.8M in total across 2 funding rounds.
GeneQuantum Healthcare has raised $20.8M across 2 funding rounds. Most recently, it raised $15.0M Series B in May 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| May 1, 2019 | $15M Series B | Huagai Capital | IDG Capital, Hofon Capital, TF Capital | Announced |
| Mar 28, 2017 | $5.8M Series A | — | TF Capital | Announced |
GeneQuantum Healthcare has raised $20.8M in total across 2 funding rounds.
GeneQuantum Healthcare's investors include Huagai Capital, IDG Capital, Hofon Capital, TF Capital.
GeneQuantum Healthcare (Suzhou) Co., Ltd. is a high-tech biopharmaceutical company headquartered in Suzhou, China (with mentions of Beijing operations), specializing in next-generation antibody-drug conjugates (ADCs) and innovative bioconjugates for cancer treatment.[1][2][3][5] It develops products using proprietary enzymatic site-specific conjugation platforms like iLDC (intelligent continuous ligase-dependent conjugation) and iGDC, enabling ADCs with advantages such as precise drug-to-antibody ratios (DAR2/4/6/8), superior stability, wider therapeutic windows, and manufacturability in standard monoclonal antibody facilities.[1][2][3][4] The company serves global cancer patients by addressing unmet needs through a pipeline of over 5 clinical-stage programs, including lead candidate GQ1005 (HER2 ADC) in Phase III and GQ1001 (world’s first site-specific transpeptidase-catalyzed ADC) in global multi-center trials funded by China’s national major new drug program.[2][3] Recognized as a "Unicorn-to-Be" by Suzhou authorities, GeneQuantum has secured $6.7M in funding, executed 4 out-licensing deals worth $13B in 2024 milestones, and drives growth via partnerships with Biohaven, AimedBio, PyramidBio, and others.[2][3][6]
Founded in 2013 by Gang Qin, who serves as Founder and CEO, GeneQuantum emerged from a vision to pioneer enzymatic site-specific conjugation for bioconjugates, filling gaps in ADC efficacy and safety.[3] Qin's leadership draws from a team of experts: CSO with experience at Eli Lilly, Samsung Bioepis, and Curon Biopharmaceutical, focusing on iLDC/iGDC tech and pipelines; CBDO with BD roles at SciClone, Pfizer, and J&J; and CMC leads with PhDs from top universities.[1] Early traction came from developing the iLDC platform, leading to GQ1001's IND approval and global trials, plus government recognitions like Nanjing and Suzhou talent awards.[1][2] Pivotal moments include 2023-2024 partnerships (e.g., $1B PyramidBio deal, AimedBio expansion) and 2024's record out-licensing, propelling it to "Unicorn-to-Be" status.[2][3][4]
GeneQuantum rides the ADC boom, a $10B+ market exploding due to approvals like Enhertu and demand for precision oncology beyond traditional chemotherapies.[3] Its timing leverages post-2020 conjugation breakthroughs, positioning enzymatic tech as superior to chemical linkers for safer, more potent drugs amid global cancer burden (20M+ cases/year).[2][4] Market forces favoring it include China’s biopharma push (national funding, Suzhou ecosystem), US/EU trial access, and outsourcing trends via high-value licenses to Western firms.[1][2][3] It influences the ecosystem by democratizing ADC manufacturing (cheaper, scalable), enabling multi-target expansions, and accelerating "best-in-class" therapies, potentially reshaping conjugate standards.[3][4]
GeneQuantum's next catalysts include September 2025 data readouts and potential China registration for GQ1005, building on 2024's BD frenzy.[3] Trends like dual-payload ADCs, oral conjugates, and AI-optimized payloads will amplify its platforms, with 10+ assets fueling more $B-scale deals.[3][6] Its influence may evolve from Chinese innovator to global ADC powerhouse, outpacing rivals via tech superiority—watch for US approvals and IPO as it delivers on the promise of accessible, transformative cancer biotherapeutics.[2][3]